Jonathan Lovell

PhD

UB Distinguished Professor

Nanomedicine; phototherapy

Buffalo NY, 14260

Phone: (716) 645-1020

Fax: (716) 645-2207

POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)
9/27/24
The Associated Press reported that POP Biotechnologies, founded by Jonathan Lovell, completed a study on a new recombinant COVID vaccine, EuCorVac-19.
UB professor, New York State researchers developing new immunotherapy treatment for Alzheimer’s disease
9/3/24
Promising approach targets multiple pathogenic hallmarks of the disease.
Promising immunotherapy treatment targets multiple pathogenic hallmarks of Alzheimer's disease
9/2/24
Medical Xpress quoted Jonathan Lovell in an article about developing a novel immunotherapy approach to Alzheimer’s disease treatment that targets multiple epitopes.
POP BIO and FunPep Announce Collaboration for Antibody-Inducing Peptide Therapy
8/18/24
EIN Newswire reported that Pop Biotech, a biotechnology company developed by Jonathan Lovell, has developed an antibody-inducing peptide therapy.
POP BIO and EuBiologics’ Shingles Vaccine Enters Phase 1 Clinical Trials
8/9/24
EIN Presswire reported that a biotech company founded by Johnathan Lovel, POP Biotechnologies, has moved into phase one of clinical trials for their new shingles vaccine.